AbbVie’s Produodopa: Potential first-choice pump for Advanced PD
The smaller size of the Produodopa pump is regarded as an advantage over Duodopa and is a welcomed option that does not require invasive surgical procedures.
Brands
Can Gilead shake up the ASCT-ineligible large B-cell lymphoma market?
JNJ-2113 results on skin clearance shows potential for psoriasis
Oral JAK inhibitors unlikely to be totally shut out in eczema by black box warning
Regulatory roundup: Novartis rare disease drug sees approval chances rise after trial completes
Regulatory roundup: BMS’s T lymphocyte immunotherapy tripped by lung cancer trial termination
Regulatory roundup: Ology, MaxCyte make moves in women’s cancer with divergent approval chances
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
